| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MED22 |
| Uniprot No | Q15528 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-140aa |
| 活性数据 | MAQQRALPQSKETLLQSYNKRLKDDIKSIMDNFTEIIKTAKIEDETQVSRATQGEQDNYEMHVRAANIVRAGESLMKLVSDLKQFLILNDFPSVNEAIDQRNQQLRTLQEECDRKLITLRDEISIDLYELEEEYYSSRYK |
| 分子量 | 42.9 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人MED22蛋白的3篇参考文献示例(文献信息为虚构，仅作示例参考)：
---
1. **文献名称**：Structural and functional characterization of recombinant human MED22 protein
**作者**：Chen L, et al.
**摘要**：本研究通过原核表达系统成功纯化重组人MED22蛋白，并利用X射线晶体学解析其三维结构，揭示了其在中介体复合体(Mediator complex)中结合RNA聚合酶II的关键结构域，为研究转录调控机制提供依据。
---
2. **文献名称**：MED22 modulates transcriptional elongation in cancer cells via interaction with cyclin-dependent kinases
**作者**：Park JH, et al.
**摘要**：通过体外重组MED22蛋白与CDK9的共沉淀实验，发现MED22通过介导中介体复合体与CDK9的相互作用，调控乳腺癌细胞中致癌基因的转录延伸过程，靶向此通路可抑制肿瘤生长。
---
3. **文献名称**：Development of a MED22-deficient cellular model using CRISPR-Cas9 and rescue with recombinant MED22
**作者**：Gupta R, et al.
**摘要**：利用CRISPR-Cas9敲除HEK293细胞中的MED22基因，导致基因全局转录效率下降;通过导入重组MED22蛋白可部分恢复中介体复合体功能，证明其在维持转录起始复合体稳定性中的必要性。
---
注：以上文献为示例性质，实际研究中请参考真实发表的论文。
**Background of Recombinant Human MED22 Protein**
The mediator complex subunit 22 (MED22), also known as Sur2. is a key component of the multi-protein Mediator complex, which plays a central role in regulating RNA polymerase II (Pol II)-dependent transcription in eukaryotes. The Mediator complex acts as a molecular bridge, facilitating communication between transcription factors and the basal transcriptional machinery. MED22. specifically, contributes to the structural integrity and functional dynamics of the Mediator complex, enabling precise modulation of gene expression in response to developmental, environmental, or cellular signals.
Recombinant human MED22 protein is engineered through molecular cloning and expression in heterologous systems (e.g., *E. coli* or mammalian cells), allowing large-scale production for functional and structural studies. Its recombinant form retains the ability to interact with other Mediator subunits and participate in transcriptional regulation. Studies using recombinant MED22 have provided insights into its role in chromatin remodeling, enhancer-promoter looping, and the recruitment of co-activators or repressors. Dysregulation of MED22 has been linked to diseases such as cancers and developmental disorders, underscoring its therapeutic potential.
Recent research focuses on characterizing MED22's interactions within the Mediator complex, its post-translational modifications, and its tissue-specific roles. Recombinant MED22 serves as a vital tool for deciphering transcriptional mechanisms and developing targeted therapies.
×
